-
1
-
-
70449435723
-
Definition and classification of hypertension: An update
-
Giles TD, Materson BJ, Cohn JN, Kostis JB. Definition and classification of hypertension: an update. J Clin Hypertens (Greenwich). 2009;11(11):611-614.
-
(2009)
J Clin Hypertens (Greenwich)
, vol.11
, Issue.11
, pp. 611-614
-
-
Giles, T.D.1
Materson, B.J.2
Cohn, J.N.3
Kostis, J.B.4
-
2
-
-
0037079309
-
Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies
-
Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-1913.
-
(2002)
Lancet
, vol.360
, Issue.9349
, pp. 1903-1913
-
-
Lewington, S.1
Clarke, R.2
Qizilbash, N.3
Peto, R.4
Collins, R.5
-
3
-
-
0035522330
-
Impact of high-normal blood pressure on the risk of cardiovascular disease
-
Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345(18):1291-1297.
-
(2001)
N Engl J Med
, vol.345
, Issue.18
, pp. 1291-1297
-
-
Vasan, R.S.1
Larson, M.G.2
Leip, E.P.3
-
4
-
-
0037429639
-
Management of high blood pressure in African Americans: Consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks
-
Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003;163(5):525-541.
-
(2003)
Arch Intern Med
, vol.163
, Issue.5
, pp. 525-541
-
-
Douglas, J.G.1
Bakris, G.L.2
Epstein, M.3
-
5
-
-
0347423198
-
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
-
Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-1252.
-
(2003)
Hypertension
, vol.42
, Issue.6
, pp. 1206-1252
-
-
Chobanian, A.V.1
Bakris, G.L.2
Black, H.R.3
-
6
-
-
33847633400
-
Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004
-
Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49(1):69-75.
-
(2007)
Hypertension
, vol.49
, Issue.1
, pp. 69-75
-
-
Ong, K.L.1
Cheung, B.M.2
Man, Y.B.3
Lau, C.P.4
Lam, K.S.5
-
7
-
-
37149026076
-
Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003-2004
-
Wong ND, Lopez VA, L'Italien G, Chen R, Kline SE, Franklin SS. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003-2004. Arch Intern Med. 2007; 167(22):2431-2436.
-
(2007)
Arch Intern Med
, vol.167
, Issue.22
, pp. 2431-2436
-
-
Wong, N.D.1
Lopez, V.A.2
L'italien, G.3
Chen, R.4
Kline, S.E.5
Franklin, S.S.6
-
8
-
-
0036863587
-
Success and predictors of blood pressure control in diverse North American settings: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
-
Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4(6):393-404.
-
(2002)
J Clin Hypertens (Greenwich)
, vol.4
, Issue.6
, pp. 393-404
-
-
Cushman, W.C.1
Ford, C.E.2
Cutler, J.A.3
-
9
-
-
24644443331
-
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial
-
Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906.
-
(2005)
Lancet
, vol.366
, Issue.9489
, pp. 895-906
-
-
Dahlöf, B.1
Sever, P.S.2
Poulter, N.R.3
-
10
-
-
0037145856
-
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial
-
Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002; 288(19):2421-2431.
-
(2002)
JAMA
, vol.288
, Issue.19
, pp. 2421-2431
-
-
Wright Jr., J.T.1
Bakris, G.2
Greene, T.3
-
11
-
-
70449851433
-
Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document
-
Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121-2158.
-
(2009)
J Hypertens
, vol.27
, pp. 2121-2158
-
-
Mancia, G.1
Laurent, S.2
Agabiti-Rosei, E.3
-
12
-
-
58049112068
-
Combining RAAS and calcium channel blockade: ACCOMPLISH in perspective
-
Kjeldsen SE, Weber M, Oparil S, Jamerson KA. Combining RAAS and calcium channel blockade: ACCOMPLISH in perspective. Blood Press. 2008;17(5-6):260-269.
-
(2008)
Blood Press
, vol.17
, Issue.5-6
, pp. 260-269
-
-
Kjeldsen, S.E.1
Weber, M.2
Oparil, S.3
Jamerson, K.A.4
-
13
-
-
57349138291
-
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients
-
Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-2428.
-
(2008)
N Engl J Med
, vol.359
, Issue.23
, pp. 2417-2428
-
-
Jamerson, K.1
Weber, M.A.2
Bakris, G.L.3
-
14
-
-
2942695964
-
Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial
-
Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363(9426):2049-2051.
-
(2004)
Lancet
, vol.363
, Issue.9426
, pp. 2049-2051
-
-
Weber, M.A.1
Julius, S.2
Kjeldsen, S.E.3
-
15
-
-
11144356621
-
Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial
-
Staessen JA, Thijisq L, Fagard R, et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens. 2004;22(4):847-857.
-
(2004)
J Hypertens
, vol.22
, Issue.4
, pp. 847-857
-
-
Staessen, J.A.1
Thijisq, L.2
Fagard, R.3
-
16
-
-
33845902544
-
The cardiovascular disease continuum validated: Clinical evidence of improved patient outcomes: Part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease)
-
Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006;114(25): 2850-2870.
-
(2006)
Circulation
, vol.114
, Issue.25
, pp. 2850-2870
-
-
Dzau, V.J.1
Antman, E.M.2
Black, H.R.3
-
17
-
-
0035048905
-
Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis
-
Dzau VJ. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension. 2001;37(4):1047-1052.
-
(2001)
Hypertension
, vol.37
, Issue.4
, pp. 1047-1052
-
-
Dzau, V.J.1
-
18
-
-
0022271856
-
End-state renal failure in diabetic nephropathy: Pathophysiology and treatment
-
Schmitz O, Hansen HE, Orskov H, Mogensen CE, Posborg Petersen V. End-state renal failure in diabetic nephropathy: pathophysiology and treatment. Blood Purif. 1985;3(1-3):120-139.
-
(1985)
Blood Purif
, vol.3
, Issue.1-3
, pp. 120-139
-
-
Schmitz, O.1
Hansen, H.E.2
Orskov, H.3
Mogensen, C.E.4
Posborg, P.V.5
-
19
-
-
0035922441
-
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
-
Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-869.
-
(2001)
N Engl J Med
, vol.345
, Issue.12
, pp. 861-869
-
-
Brenner, B.M.1
Cooper, M.E.2
de Zeeuw, D.3
-
20
-
-
44849114597
-
Aliskiren combined with losartan in type 2 diabetes and nephropathy
-
Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358(23):2433-2446.
-
(2008)
N Engl J Med
, vol.358
, Issue.23
, pp. 2433-2446
-
-
Parving, H.H.1
Persson, F.2
Lewis, J.B.3
Lewis, E.J.4
Hollenberg, N.K.5
-
21
-
-
0031015833
-
Plasma renin activity: A risk factor for myocardial infarction in hypertensive patients
-
Alderman MH, Ooi WL, Cohen H, Madhavan S, Sealey JE, Laragh JH. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens. 1997;10(1):1-8.
-
(1997)
Am J Hypertens
, vol.10
, Issue.1
, pp. 1-8
-
-
Alderman, M.H.1
Ooi, W.L.2
Cohen, H.3
Madhavan, S.4
Sealey, J.E.5
Laragh, J.H.6
-
22
-
-
77955928113
-
Plasma renin activity is associated with increased cardiovascular events and mortality in the HOPE study
-
Abstract 1134
-
Verma S, Gupta M, Holmes DT, et al. 2009. Plasma renin activity is associated with increased cardiovascular events and mortality in the HOPE study. Circulation. 120:S453. Abstract 1134.
-
(2009)
Circulation
, vol.120
-
-
Verma, S.1
Gupta, M.2
Holmes, D.T.3
-
23
-
-
70349218543
-
Association between baseline levels of plasma renin activity and risk of cardiovascular events
-
Abstract 1028-12
-
Bair TL, May HT, Prescott MF, et al. 2009. Association between baseline levels of plasma renin activity and risk of cardiovascular events. J Am Coll Cardiol. 53(10 Suppl A):A383. Abstract 1028-12.
-
(2009)
J Am Coll Cardiol
, vol.53
, Issue.10 SUPPL A
-
-
Bair, T.L.1
May, H.T.2
Prescott, M.F.3
-
24
-
-
72549105303
-
Aldosterone and cardiovascular risk
-
Vogt B, Burnier M. Aldosterone and cardiovascular risk. Curr Hypertens Rep. 2009;11(6):450-455.
-
(2009)
Curr Hypertens Rep
, vol.11
, Issue.6
, pp. 450-455
-
-
Vogt, B.1
Burnier, M.2
-
25
-
-
33646580336
-
ACE inhibitor-angiotensin receptor blocker combinations: A clinician's perspective
-
Doulton TW. ACE inhibitor-angiotensin receptor blocker combinations: a clinician's perspective. Mini Rev Med Chem. 2006;6(5):491-497.
-
(2006)
Mini Rev Med Chem
, vol.6
, Issue.5
, pp. 491-497
-
-
Doulton, T.W.1
-
26
-
-
73349128134
-
Recent changes in the landscape of combination RAS blockade
-
Epstein BJ, Smith SM, Choksi R. Recent changes in the landscape of combination RAS blockade. Expert Rev Cardiovasc Ther. 2009;7(11):1373-1384.
-
(2009)
Expert Rev Cardiovasc Ther
, vol.7
, Issue.11
, pp. 1373-1384
-
-
Epstein, B.J.1
Smith, S.M.2
Choksi, R.3
-
27
-
-
36349036058
-
Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus
-
Yoneda T, Takeda Y, Usukura M, et al. Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. Am J Hypertens. 2007;20(12):1329-1333.
-
(2007)
Am J Hypertens
, vol.20
, Issue.12
, pp. 1329-1333
-
-
Yoneda, T.1
Takeda, Y.2
Usukura, M.3
-
28
-
-
34548163060
-
The incidence and implications of aldosterone breakthrough
-
Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol. 2007;3(9):486-492.
-
(2007)
Nat Clin Pract Nephrol
, vol.3
, Issue.9
, pp. 486-492
-
-
Bomback, A.S.1
Klemmer, P.J.2
-
29
-
-
73349127055
-
Aliskiren, the first approved renin inhibitor: Clinical application and safety in the treatment of hypertension
-
Riccioni G, Vitulano N, D'Orazio N, Bellocci F. Aliskiren, the first approved renin inhibitor: Clinical application and safety in the treatment of hypertension. Adv Ther. 2009;26(7):700-710.
-
(2009)
Adv Ther
, vol.26
, Issue.7
, pp. 700-710
-
-
Riccioni, G.1
Vitulano, N.2
D'orazio, N.3
Bellocci, F.4
-
30
-
-
18244406792
-
Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension
-
Doulton TW, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension. 2005;45(5):880-886.
-
(2005)
Hypertension
, vol.45
, Issue.5
, pp. 880-886
-
-
Doulton, T.W.1
He, F.J.2
Macgregor, G.A.3
-
31
-
-
42049107348
-
Telmisartan, ramipril, or both in patients at high risk for vascular events
-
Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358(15): 1547-1559.
-
(2008)
N Engl J Med
, vol.358
, Issue.15
, pp. 1547-1559
-
-
Yusuf, S.1
Teo, K.K.2
Pogue, J.3
-
32
-
-
49149087718
-
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial
-
Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547-553.
-
(2008)
Lancet
, vol.372
, Issue.9638
, pp. 547-553
-
-
Mann, J.F.1
Schmieder, R.E.2
McQueen, M.3
-
33
-
-
34548444609
-
Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus
-
Hollenberg NK, Parving HH, Viberti G, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens. 2007;25(9):1921-1926.
-
(2007)
J Hypertens
, vol.25
, Issue.9
, pp. 1921-1926
-
-
Hollenberg, N.K.1
Parving, H.H.2
Viberti, G.3
-
34
-
-
36248931664
-
The renin-angiotensin aldosterone system: Pathophysiological role and pharmacologic inhibition
-
Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007; 13(8 Suppl S-b):S9-S20.
-
(2007)
J Manag Care Pharm
, vol.13
, Issue.8 SUPPL S-B
-
-
Atlas, S.A.1
-
35
-
-
0028017360
-
Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: Effect of captopril
-
Rouleau JL, Packer M, Moye L, et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol. 1994;24(3):583-591.
-
(1994)
J Am Coll Cardiol
, vol.24
, Issue.3
, pp. 583-591
-
-
Rouleau, J.L.1
Packer, M.2
Moye, L.3
-
36
-
-
10744232800
-
The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT
-
Latini R, Masson S, Anand I, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J. 2004;25(4):292-299.
-
(2004)
Eur Heart J
, vol.25
, Issue.4
, pp. 292-299
-
-
Latini, R.1
Masson, S.2
Anand, I.3
-
37
-
-
33846421005
-
Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker
-
O'Brien E, Barton J, Nussberger J, et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension. 2007;49(2):276-284.
-
(2007)
Hypertension
, vol.49
, Issue.2
, pp. 276-284
-
-
O'Brien, E.1
Barton, J.2
Nussberger, J.3
-
38
-
-
38649102508
-
Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension
-
Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst. 2007;8(4):190-198.
-
(2007)
J Renin Angiotensin Aldosterone Syst
, vol.8
, Issue.4
, pp. 190-198
-
-
Uresin, Y.1
Taylor, A.A.2
Kilo, C.3
-
39
-
-
47049093197
-
Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans
-
Fisher ND, Jan Danser AH, Nussberger J, Dole WP, Hollenberg NK. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation. 2008;117(25):3199-3205.
-
(2008)
Circulation
, vol.117
, Issue.25
, pp. 3199-3205
-
-
Fisher, N.D.1
Jan, D.A.H.2
Nussberger, J.3
Dole, W.P.4
Hollenberg, N.K.5
-
40
-
-
70349690296
-
Renal effects of aliskiren compared to and in combination with irbesartan in patients with type 2 diabetes, hypertension and albuminuria
-
Persson F, Rossing P, Reinhard H, et al. Renal effects of aliskiren compared to and in combination with irbesartan in patients with type 2 diabetes, hypertension and albuminuria. Diabetes Care. 2009;32(10): 1873-1879.
-
(2009)
Diabetes Care
, vol.32
, Issue.10
, pp. 1873-1879
-
-
Persson, F.1
Rossing, P.2
Reinhard, H.3
-
41
-
-
79958249630
-
Effects of the oral direct rennin inhibitor aliskiren in patients with symptomatic heart failure
-
McMurray JJ, Pitt B, Latini R, et al. Effects of the oral direct rennin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008;1:17-24.
-
(2008)
Circ Heart Fail
, vol.1
, pp. 17-24
-
-
McMurray, J.J.1
Pitt, B.2
Latini, R.3
-
42
-
-
61349170589
-
Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy
-
Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009;119(4):530-537.
-
(2009)
Circulation
, vol.119
, Issue.4
, pp. 530-537
-
-
Solomon, S.D.1
Appelbaum, E.2
Manning, W.J.3
-
43
-
-
36649012323
-
Renin system suppression with the oral direct renin inhibitor aliskiren administered alone or in combination: A pooled analysis of 1093 patients with hypertension
-
Abstract 1014-1170
-
Taylor AA, Anderson DR, Arora V, et al. 2007. Renin system suppression with the oral direct renin inhibitor aliskiren administered alone or in combination: a pooled analysis of 1093 patients with hypertension. J Am Coll Cardiol. 49(9 Suppl A):370A. Abstract 1014-1170.
-
(2007)
J Am Coll Cardiol
, vol.49
, Issue.9 SUPPL A
-
-
Taylor, A.A.1
Anderson, D.R.2
Arora, V.3
-
44
-
-
9644287897
-
Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption
-
Azizi M, Ménard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol. 2004;15(12):3126-3133.
-
(2004)
J Am Soc Nephrol
, vol.15
, Issue.12
, pp. 3126-3133
-
-
Azizi, M.1
Ménard, J.2
Bissery, A.3
-
45
-
-
69849112971
-
Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension
-
Andersen K, Weinberger MH, Constance CC, et al. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension. J Renin Angiotensin Aldosterone Syst. 2009;10(3):157-167.
-
(2009)
J Renin Angiotensin Aldosterone Syst
, vol.10
, Issue.3
, pp. 157-167
-
-
Andersen, K.1
Weinberger, M.H.2
Constance, C.C.3
-
47
-
-
34447521458
-
Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial
-
Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007;370(9583):221-229.
-
(2007)
Lancet
, vol.370
, Issue.9583
, pp. 221-229
-
-
Oparil, S.1
Yarows, S.A.2
Patel, S.3
Fang, H.4
Zhang, J.5
Satlin, A.6
-
48
-
-
69849114573
-
Aliskiren and valsartan in stage 2 hypertension: Subgroup analysis of a randomized, doubleblind study
-
Yarows SA, Oparil S, Patel S, Fang H, Zhang J. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, doubleblind study. Adv Ther. 2008;25(12):1288-1302.
-
(2008)
Adv Ther
, vol.25
, Issue.12
, pp. 1288-1302
-
-
Yarows, S.A.1
Oparil, S.2
Patel, S.3
Fang, H.4
Zhang, J.5
-
49
-
-
42549113198
-
Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: A 6-month interim analysis
-
Chrysant SG, Murray AV, Hoppe UC, et al. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Curr Med Res Opin. 2008;24(4):1039-1047.
-
(2008)
Curr Med Res Opin
, vol.24
, Issue.4
, pp. 1039-1047
-
-
Chrysant, S.G.1
Murray, A.V.2
Hoppe, U.C.3
-
50
-
-
33845785350
-
Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan
-
Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007;20(1):11-20.
-
(2007)
Am J Hypertens
, vol.20
, Issue.1
, pp. 11-20
-
-
Pool, J.L.1
Schmieder, R.E.2
Azizi, M.3
-
51
-
-
34250179723
-
Fixed-dose combinations improve medication compliance: A meta-analysis
-
Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713-719.
-
(2007)
Am J Med
, vol.120
, Issue.8
, pp. 713-719
-
-
Bangalore, S.1
Kamalakkannan, G.2
Parkar, S.3
Messerli, F.H.4
-
52
-
-
64149083424
-
Issues in blood pressure control and the potential role of single-pill combination therapies
-
Burnier M, Brown RE, Ong SH, Keskinaslan A, Khan ZM. Issues in blood pressure control and the potential role of single-pill combination therapies. Int J Clin Pract. 2009;63(5):790-798.
-
(2009)
Int J Clin Pract
, vol.63
, Issue.5
, pp. 790-798
-
-
Burnier, M.1
Brown, R.E.2
Ong, S.H.3
Keskinaslan, A.4
Khan, Z.M.5
-
53
-
-
60549100908
-
An issue of dependence: Implications from the Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial
-
Riche DM, Minor DS, Holdiness AS, East HE. An issue of dependence: implications from the Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial. J Clin Hypertens (Greenwich). 2009;11(2):89-93.
-
(2009)
J Clin Hypertens (Greenwich)
, vol.11
, Issue.2
, pp. 89-93
-
-
Riche, D.M.1
Minor, D.S.2
Holdiness, A.S.3
East, H.E.4
-
54
-
-
0037417252
-
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
-
Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309-1321.
-
(2003)
N Engl J Med
, vol.348
, Issue.14
, pp. 1309-1321
-
-
Pitt, B.1
Remme, W.2
Zannad, F.3
-
55
-
-
0033517302
-
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators
-
Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709-717.
-
(1999)
N Engl J Med
, vol.341
, Issue.10
, pp. 709-717
-
-
Pitt, B.1
Zannad, F.2
Remme, W.J.3
-
56
-
-
0037116558
-
Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: Role of vascular superoxide anion formation and endothelial nitric oxide synthase expression
-
Bauersachs J, Heck M, Fraccarollo D, et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol. 2002;39(2):351-358.
-
(2002)
J Am Coll Cardiol
, vol.39
, Issue.2
, pp. 351-358
-
-
Bauersachs, J.1
Heck, M.2
Fraccarollo, D.3
-
57
-
-
0037035471
-
Mineralocorticoid receptor antagonism in experimental atherosclerosis
-
Rajagopalan S, Duquaine D, King S, Pitt B, Patel P. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation. 2002;105(18):2212-2216.
-
(2002)
Circulation
, vol.105
, Issue.18
, pp. 2212-2216
-
-
Rajagopalan, S.1
Duquaine, D.2
King, S.3
Pitt, B.4
Patel, P.5
-
58
-
-
65249182083
-
Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): Rationale and study design
-
Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant. 2009;24(5):1663-1671.
-
(2009)
Nephrol Dial Transplant
, vol.24
, Issue.5
, pp. 1663-1671
-
-
Parving, H.H.1
Brenner, B.M.2
McMurray, J.J.3
-
59
-
-
66149177166
-
Cardio-renal protection with aliskiren, a direct renin inhibitor, in the ASPIRE HIGHER program
-
Lee HY, Oh BH. Cardio-renal protection with aliskiren, a direct renin inhibitor, in the ASPIRE HIGHER program. Expert Rev Cardiovasc Ther. 2009;7(3):251-257.
-
(2009)
Expert Rev Cardiovasc Ther
, vol.7
, Issue.3
, pp. 251-257
-
-
Lee, H.Y.1
Oh, B.H.2
-
60
-
-
54949156830
-
Renal hemodynamics and renoprotection
-
Loriga G, Vidili G, Ruggenenti P, Faedda R, Sanna M, Satta AE. Renal hemodynamics and renoprotection. Nephron Clin Pract. 2008;110(4):c213-c219.
-
(2008)
Nephron Clin Pract
, vol.110
, Issue.4
-
-
Loriga, G.1
Vidili, G.2
Ruggenenti, P.3
Faedda, R.4
Sanna, M.5
Satta, A.E.6
-
61
-
-
36248931230
-
Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy
-
Drummond W, Munger MA, Rafique EM, Maboudian M, Khan M, Keefe DL. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens (Greenwich). 2007;9(10):742-750.
-
(2007)
J Clin Hypertens (Greenwich)
, vol.9
, Issue.10
, pp. 742-750
-
-
Drummond, W.1
Munger, M.A.2
Rafique, E.M.3
Maboudian, M.4
Khan, M.5
Keefe, D.L.6
-
62
-
-
33845366982
-
Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide
-
Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007;25(1):217-226.
-
(2007)
J Hypertens
, vol.25
, Issue.1
, pp. 217-226
-
-
Villamil, A.1
Chrysant, S.G.2
Calhoun, D.3
-
63
-
-
0034688194
-
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators
-
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145-153.
-
(2000)
N Engl J Med
, vol.342
, Issue.3
, pp. 145-153
-
-
Yusuf, S.1
Sleight, P.2
Pogue, J.3
Bosch, J.4
Davies, R.5
Dagenais, G.6
-
64
-
-
0023266532
-
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
-
The CONSENSUS Trial Study Group
-
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987;316(23):1429-1435.
-
(1987)
N Engl J Med
, vol.316
, Issue.23
, pp. 1429-1435
-
-
-
65
-
-
0025913812
-
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
-
The SOLVD Investigators
-
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991;325(5):293-302.
-
(1991)
N Engl J Med
, vol.325
, Issue.5
, pp. 293-302
-
-
-
66
-
-
0035818884
-
A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure
-
Cohn JN, Tognoni G. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667-1675.
-
(2001)
N Engl J Med
, vol.345
, Issue.23
, pp. 1667-1675
-
-
Cohn, J.N.1
Tognoni, G.2
-
67
-
-
0037160968
-
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
-
Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995-1003.
-
(2002)
Lancet
, vol.359
, Issue.9311
, pp. 995-1003
-
-
Dahlöf, B.1
Devereux, R.B.2
Kjeldsen, S.E.3
-
68
-
-
0041909380
-
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial
-
Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362(9386):772-776.
-
(2003)
Lancet
, vol.362
, Issue.9386
, pp. 772-776
-
-
Granger, C.B.1
McMurray, J.J.2
Yusuf, S.3
-
69
-
-
0035922447
-
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
-
Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-860.
-
(2001)
N Engl J Med
, vol.345
, Issue.12
, pp. 851-860
-
-
Lewis, E.J.1
Hunsicker, L.G.2
Clarke, W.R.3
-
70
-
-
0242490542
-
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
-
Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893-1906.
-
(2003)
N Engl J Med
, vol.349
, Issue.20
, pp. 1893-1906
-
-
Pfeffer, M.A.1
McMurray, J.J.2
Velazquez, E.J.3
-
71
-
-
0041408235
-
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial
-
McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362(9386):767-771.
-
(2003)
Lancet
, vol.362
, Issue.9386
, pp. 767-771
-
-
McMurray, J.J.1
Ostergren, J.2
Swedberg, K.3
-
72
-
-
0034627208
-
Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study
-
Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321(7274):1440-1444.
-
(2000)
BMJ
, vol.321
, Issue.7274
, pp. 1440-1444
-
-
Mogensen, C.E.1
Neldam, S.2
Tikkanen, I.3
-
73
-
-
34648820103
-
Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE trial
-
Bakris GL, Ruilope L, Locatelli F, et al. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int. 2007;72(7):879-885.
-
(2007)
Kidney Int
, vol.72
, Issue.7
, pp. 879-885
-
-
Bakris, G.L.1
Ruilope, L.2
Locatelli, F.3
|